A neoantigen-targeting personalized cancer vaccine may be effective as adjuvant therapy in patients with high-risk clear cell renal cell carcinoma, phase 1 data suggest.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback